Get the Stockscreener App
6.00
10.58%
-0.71
Apollomics Inc stock is traded at $6.00, with a volume of 20,726.
It is down -10.58% in the last 24 hours and down -8.20% over the past month.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
See More
Previous Close:
$6.71
Open:
$6.58
24h Volume:
20,726
Relative Volume:
0.97
Market Cap:
$6.62M
Revenue:
-
Net Income/Loss:
$-57.11M
P/E Ratio:
-0.40
EPS:
-15
Net Cash Flow:
$-34.82M
1W Performance:
-21.16%
1M Performance:
-8.20%
6M Performance:
-62.03%
1Y Performance:
-90.16%
1-Day Range:
$4.9501
$6.58
1-Week Range:
$4.9501
$8.70
52-Week Range:
$4.9501
$61.00
Apollomics Inc Stock (APLM) Company Profile
Compare APLM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLM
Apollomics Inc
|
6.00 | 6.62M | 0 | -57.11M | -34.82M | -15.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Apollomics Inc Stock (APLM) Latest News
(APLM) Investment Analysis - news.stocktradersdaily.com
APLM stock touches 52-week low at $6 amid market challenges - Investing.com Australia
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress - The Manila Times
Apollomics Achieves Major Clinical Win: 43% Response Rate Plus New $10M Partnership Deal Extends Runway - Stock Titan
Apollomics and LaunXP ink $50 M deal for NSCLC treatment in Asia - BioSpectrum Asia
Apollomics and LaunXP agree on NSCLC treatment in Asia - Yahoo
Apollomics, Inc. (NASDAQ:APLMW) Sees Significant Growth in Short Interest - Defense World
Apollomics, LaunXP enter development, commercial agreement for Vebreltinib - MSN
Apollomics Signs Exclusive Development, Commercialization Deal for Vebreltinib in Asia - MarketScreener
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib - GlobeNewswire
$60M Deal: Apollomics' Lung Cancer Drug Breakthrough Expands Across Asia - Stock Titan
Better Artificial Intelligence Stock: SoundHound AI vs. C3.ai - The Globe and Mail
Apollomics Inc. and LaunXP International Co., Ltd., Affiliate of LaunXP Biomedical Co., Ltd. Announce Development and Commercialization Agreement for Vebreltinib - MarketScreener
(APLM) Long Term Investment Analysis - news.stocktradersdaily.com
Why Coinbase (COIN) Stock Is Trading Up Today - The Globe and Mail
Apollomics, Inc. (NASDAQ:APLMW) Short Interest Update - Defense World
These Were the 2 Top-Performing Stocks in the S&P 500 in February 2025 - The Globe and Mail
(APLM) Trading Advice - Stock Traders Daily
Apollomics, Inc. (NASDAQ:APLMW) Sees Large Decrease in Short Interest - Defense World
APLM Stock Hits 52-Week Low at $6.2 Amid Steep Yearly Decline - Investing.com Australia
APLM Stock Hits 52-Week Low at $6.2 Amid Steep Yearly Decline By Investing.com - Investing.com South Africa
APLM stock touches 52-week low at $6.38 amid market challenges - MSN
APLM stock touches 52-week low at $6.38 amid market challenges By Investing.com - Investing.com South Africa
Objective long/short (APLM) Report - Stock Traders Daily
Apollomics, Inc. (NASDAQ:APLMW) Sees Significant Decrease in Short Interest - Defense World
Apollomics phase 3 trial in China shows no benefit - Investing.com India
Biotech fails trials for its leukemia drug - Silicon Valley Business Journal
Apollomics Shares Down in Premarket After Leukemia Drug Misses Phase-3 Targets - MarketWatch
Apollomics Announces Top-line Results for Phase 3 Bridging - GlobeNewswire
Apollomics' Cancer Drug Disappoints in Phase 3 Trial with Lower Survival Rates, Program Terminated - StockTitan
Apollomics Meets Nasdaq Compliance On Bid Price Requirement - Nasdaq
APLM Stock Hits 52-Week Low at $7.51 Amid Market Challenges - Investing.com Australia
APLM Stock Hits 52-Week Low at $7.51 Amid Market Challenges By Investing.com - Investing.com South Africa
Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement - GlobeNewswire
Apollomics Secures Nasdaq Listing Status After Meeting Crucial Price Requirements - StockTitan
When the Price of (APLM) Talks, People Listen - Stock Traders Daily
Apollomics Inc trading halted, news pending - MSN
Apollomics, Inc. Appoints Matthew Plunkett as Chief Financial Officer - Marketscreener.com
APLM Stock Plummets to 52-Week Low, Hits $8.01 Amid Market Turbulence - Investing.com India
APLM Stock Plummets to 52-Week Low, Hits $8.01 Amid Market Turbulence By Investing.com - Investing.com South Africa
Apollomics, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 - Marketscreener.com
Apollomics Shares to Reverse Split on Monday, November 25th (NASDAQ:APLM) - Defense World
Apollomics announces 1-for-100 reverse stock split By Investing.com - Investing.com South Africa
Apollomics announces 1-for-100 reverse stock split - Investing.com
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split - GlobeNewswire
Apollomics Implements 1-for-100 Reverse Stock Split, Adjusts Warrant Prices | APLM Stock News - StockTitan
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLMA Must-Watch This Week! - Marketscreener.com
Stock market today: CareMax(−41.19%), HCW Biologics(+209.06%) among the most volatile stocks in early trading - Business Upturn
Apollomics, Inc. (NASDAQ:APLM) Sees Significant Drop in Short Interest - Defense World
Apollomics Inc (APLM): Major Improvements, Need To Be Considered - Stocks Register
Apollomics Inc Stock (APLM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):